InductOs

ApprovedSmall molecule

Pfizer

InductOs is one of 5 small molecule programs targeting Tibia Fracture. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tibia FractureActive, not recruiting

Tibia FractureApproved

Active, not recruiting

Competition

Competitive Landscape

7 competitors in Tibia Fracture

#DrugCompanyPhaseTrials

Advil

KKenvue Brands

Phase 3

3 2

Genotropin

EMD Serono

Phase 2

1 3

InductOs

Pfizer

Approved

1 4

Deltavit

HHyundai Pharmaceutical Co., LTD.

Tylenol

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Bone1 trial

Lateral Ridge Augmentation Using Autogenous Bone Blocks or Xenogenic Bone Block Grafts Loaded With Recombinant Human Bone Morphogenic Protein 2

Completed·UUniversity of Zurich·Phase 3·NCT01541345·24 enrolled

Tibia Fracture1 trial

Study Evaluating InductOs in Diaphyseal Tibia Fractures

Completed· Pfizer logo

Pfizer·Phase 4·NCT00161616·277 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for InductOs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — InductOs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for InductOs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: Pfizer

InductOs

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Bone1 trial

Tibia Fracture1 trial

References

Drug Info

Quick Facts

Related News